Quintiles Launches Tissue Testing Services In China

Quintiles has announced the availability of anatomic pathology services through its central laboratory in Beijing. This is to help biopharmaceutical companies to develop more effective cancer treatments. These services complement assay development, digital pathology and core lab offerings that are available through the facility to help customers to comply with China’s restrictions on tissue import/export.

“Within China, we are providing the tools and infrastructure to investigate cancer and match patients with optimum treatments for their genetic makeup,” said Christopher Ung, VP Strategic Business and Operations, Oncology for Quintiles. “These capabilities enable personalized medicine and enhance oncology research to bring medicines to market faster.”

“The China anatomic pathology lab and continued biomarker assay development will help our customers to navigate risk and seize opportunities in the New Health – which we see as an era of change in the biopharma industry,” said Thomas Wollman, Senior VP, Global Central Labs. “The China facility is part of our globally harmonized lab network.”

The anatomic pathology lab was accredited by the College of American Pathologists (CAP).